Neurotech Device Sector Shows Growth, But Challenges Await
This article was originally published in The Gray Sheet
Executive Summary
Participants at the recent Neurotech Investing and Partnering Conference are generally optimistic about the commercial potential for neurotechnology.
You may also be interested in...
FDA Advisory Panel Supports NeuroPace’s RNS Neurostimulator
Neurological devices panel votes in favor of device intended to reduce epileptic seizures despite lingering questions about the trial results.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.